<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03410056</url>
  </required_header>
  <id_info>
    <org_study_id>20170149</org_study_id>
    <secondary_id>2017-001944-36</secondary_id>
    <nct_id>NCT03410056</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Efavaleukin Alfa in Subjects With Active Rheumatoid Arthritis</brief_title>
  <official_title>A Phase 1b/2a Study to Evaluate the Safety and Efficacy of Efavaleukin Alfa in Subjects With Active Rheumatoid Arthritis With Inadequate Response to Standard of Care Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase 1b. To evaluate the safety and tolerability of subcutaneous (SC) dose administrations&#xD;
      of Efavaleukin alfa in subjects with active rheumatoid arthritis (RA).&#xD;
&#xD;
      Phase 2a. To evaluate the efficacy of Efavaleukin alfa at week 12 as measured by the American&#xD;
      College of Rheumatology 20 percent improvement criteria (ACR 20) in adult subjects with&#xD;
      moderate to severe RA.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Amgen made a business decision not to proceed with Phase 2.&#xD;
  </why_stopped>
  <start_date type="Actual">May 22, 2018</start_date>
  <completion_date type="Actual">May 13, 2020</completion_date>
  <primary_completion_date type="Actual">December 10, 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase 1b: Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE)</measure>
    <time_frame>Day 1 up to end of study, maximum of 18 weeks (12-weeks double-blind treatment, 6-weeks safety follow-up)</time_frame>
    <description>TEAEs were events with an onset after the administration of the first dose of study treatment.&#xD;
TEAEs were graded using the Common Terminology Criteria for Adverse Events (CTCAE).&#xD;
Grade 2 Moderate; minimal, local or noninvasive intervention indicated; limited age appropriate instrumental activities of daily life (ADL).&#xD;
Grade 3 Severe or medically significant but not immediately life-threatening; hospitalization or prolonged hospitalization indicated; disabling; limited self care ADL.&#xD;
Grade 4 Life-threatening consequences; urgent interventions indicated.&#xD;
Serious adverse events (SAEs) were defined as meeting at least 1 of the following criteria:&#xD;
Results in death (fatal)&#xD;
Immediately life-threatening&#xD;
Requires in-patient hospitalization or prolongation of existing hospitalization&#xD;
Results in persistent or significant disability/incapacity&#xD;
Is a congenital anomaly/birth defect&#xD;
Other medically important serious event</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 1b: Number of Participants Who Experienced a Clinically Significant Change in Vital Signs</measure>
    <time_frame>Baseline up to end of study, maximum of 18 weeks (12-weeks double-blind treatment, 6-weeks safety follow-up)</time_frame>
    <description>Any changes in systolic/diastolic blood pressure, heart rate, respiratory rate, and temperature that were deemed as clinically significant by the Investigator were reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 1b: Number of Participants Who Experienced a Clinically Significant Change in Laboratory Safety Tests</measure>
    <time_frame>Baseline up to end of study, maximum of 18 weeks (12-weeks double-blind treatment, 6-weeks safety follow-up)</time_frame>
    <description>Laboratory safety tests included chemistry and hematology parameters. Clinically significant laboratory safety tests were any events assessed as CTCAE Grade â‰¥3 at any post-baseline visit.&#xD;
Grade 3 Severe or medically significant but not immediately life-threatening; hospitalization or prolonged hospitalization indicated; disabling; limited self care ADL.&#xD;
Grade 4 Life-threatening consequences; urgent interventions indicated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 1b: Number of Participants Who Experienced a Clinically Significant Change in Electrocardiograms (ECGs)</measure>
    <time_frame>Baseline up to end of treatment maximum of 12 weeks</time_frame>
    <description>Any changes in ECG parameters that were deemed clinically significant by the investigator were reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 2a: Number of Participants Who Achieved an American College of Rheumatology 20 Percent Improvement Criteria (ACR 20) at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>ACR 20 response defined as at least 20 percent improvement from baseline in both tender and swollen joint counts, and a 20 percent improvement or more in at least 3 of the following 5 criteria:&#xD;
physician global assessment of disease activity (PGA)&#xD;
subject global assessment of disease activity (SGA)&#xD;
patient global assessment of joint pain&#xD;
subject self-assessment of disability (HAQ-DI)&#xD;
C-Reactive Protein (CRP)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Phase 1b: Efavaleukin Alfa Serum Concentrations</measure>
    <time_frame>Day 1 (pre-dose), 6 and 12 hours post-dose, and days 2, 3, 4, 8, 11, 15, 22, 29, 36, 43, 50, 57, 64, 71, 78, and Day 85 (pre-dose), 6 and 12 hours post-dose and days 86, 87, 88, 92, 99, 113 and 127</time_frame>
    <description>A summary of mean serum concentrations of Efavaleukin alfa over time is presented. Any results below the lower limit of quantification were set to 0.00.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1b: Maximum Observed Serum Concentration (Cmax) of Efavaleukin Alfa</measure>
    <time_frame>Day 1 (pre-dose) and 6 to 48 hours post-dose, and days 4, 8, 11, 15, 22, 29, 36, 43, 50, 57, 64, 71, 78, Day 85 (pre-dose) and 6 to 72 hours post-dose, and days 92, 99, 113 and 127</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1b: Time to Maximum Observed Serum Concentration (Tmax) of Efavaleukin Alfa</measure>
    <time_frame>Day 1 (pre-dose) and 6 to 48 hours post-dose, and days 4, 8, 11, 15, 22, 29, 36, 43, 50, 57, 64, 71, 78, Day 85 (pre-dose) and 6 to 72 hours post-dose, and days 92, 99, 113 and 127</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1b: Area Under the Concentration-time Curve From Time 0 to 14 Days (AUC0-14) Post Dose</measure>
    <time_frame>Day 1 (pre-dose) and 6 to 48 hours post-dose, and days 4, 8, 11 and 15, Day 85 (pre-dose) and 6 to 72 hours post-dose, and days 92 and 99</time_frame>
    <description>AUC0-14 was only assessed for the participants who received Efavaleukin alfa using dosing schedule A.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1b: Area Under the Concentration-time Curve From Time 0 to 7 Days (AUC0-7) Post Dose</measure>
    <time_frame>Day 1 (pre-dose) and 6 to 48 hours post-dose, and days 4 and 8, Day 85 (pre-dose) and 6 to 72 hours post-dose, and Day 92</time_frame>
    <description>AUC0-7 was only assessed for the participants who received Efavaleukin alfa using dosing schedule B.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1b: Number of Participants With Anti-Efavaleukin Alfa Binding Antibodies and Anti-Interleukin (IL-2) Binding Antibodies</measure>
    <time_frame>Baseline up to end of study, maximum of 18 weeks (12-weeks double-blind treatment, 6-weeks safety follow-up)</time_frame>
    <description>Number of participants who tested positive for anti-Efavaleukin alfa binding antibodies and number of those participants who cross-reacted with native human IL-2 (i.e. with anti-IL-2 binding antibodies) are reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1b: Number of Participants With Anti-Efavaleukin Alfa Neutralizing Antibodies and Anti-IL-2 Neutralizing Antibodies</measure>
    <time_frame>Baseline up to end of study, maximum of 18 weeks (12-weeks double-blind treatment, 6-weeks safety follow-up)</time_frame>
    <description>The number of participants who tested positive for anti-Efavaleukin alfa neutralizing antibodies and number of participants with anti-IL2 neutralizing antibodies who tested negative or no result at baseline are reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2a: Number of Participants Who Achieved an American College of Rheumatology 50 Percent Improvement Criteria (ACR 50) or 70 Percent Improvement Criteria (ACR 70) at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>ACR 50 and ACR 70 response defined as at least 50 percent or 70 percent improvement from baseline in both tender and swollen joint counts, and a 50 percent or 70 percent improvement or more in at least 3 of the following 5 criteria:&#xD;
physician global assessment of disease activity (PGA)&#xD;
subject global assessment of disease activity (SGA)&#xD;
patient global assessment of joint pain&#xD;
subject self-assessment of disability (HAQ-DI)&#xD;
C-Reactive Protein (CRP)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2a: Change From Baseline in Disease Activity Score (28 Joint) Calculated Using The Erythrocyte Sedimentation Rate Formula (DAS28-ESR) at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Change from baseline in DAS28-ER at Week 12. DAS28-ESR was to assess disease activity in patients with rheumatoid arthritis. DAS28-ESR is a composite score that includes 4 variables: tender joint count (TJC) (based on 28 joints); swollen joint count (SJC) (based on 28 joints); participant's global assessment of health activity using 100 mm VAS: range 0 (no pain) to 100 (maximum pain imaginable); marker of inflammation assessed by ESR in mm/h. DAS28-ESR total score range from 0-10, higher score indicates more disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2a: Change From Baseline in Disease Activity Score (28 Joint) Calculated Using the C-reactive Protein Formula (DAS-28-CRP) at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Change from baseline in DAS28-CRP at Week 12. 2. DAS28-CRP was to assess disease activity in patients with rheumatoid arthritis. DAS28-CRP is a composite score that includes 4 variables: TJC (based on 28 joints); SJC (based on 28 joints); participant's global assessment of health activity using 100 mm VAS: range 0 (no pain) to 100 (maximum pain imaginable); marker of inflammation assessed by CRP in mg/L. DAS28-CRP total score range from 0-10, higher score indicates more disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2a: Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE)</measure>
    <time_frame>Baseline up to end of study, maximum of 18 weeks (12-weeks double-blind treatment, 6-weeks safety follow-up)</time_frame>
    <description>TEAEs were events with an onset after the administration of the first dose of study treatment.&#xD;
TEAEs were graded using the Common Terminology Criteria for Adverse Events (CTCAE).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2a: Number of Participants Who Experienced a Clinically Significant Change in Vital Signs</measure>
    <time_frame>Baseline up to Week 12</time_frame>
    <description>Any changes in systolic/diastolic blood pressure, heart rate, respiratory rate, and temperature that were deemed as clinically significant by the Investigator were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2a: Number of Participants Who Experienced a Clinically Significant Change in Laboratory Safety Tests</measure>
    <time_frame>Day 1 up to end of study, maximum of 18 weeks (12-weeks double-blind treatment, 6-weeks safety follow-up)</time_frame>
    <description>Laboratory safety tests included chemistry and hematology parameters. Clinically significant laboratory safety tests were any events assessed as CTCAE Grade â‰¥3 at any post-baseline visit.&#xD;
Grade 3 Severe or medically significant but not immediately life-threatening; hospitalization or prolonged hospitalization indicated; disabling; limited self care ADL.&#xD;
Grade 4 Life-threatening consequences; urgent interventions indicated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2a: Efavaleukin Alfa Serum Concentration</measure>
    <time_frame>Day 1 (pre-dose) and weeks 2, 4, 6, 8, 10 and 12</time_frame>
    <description>A summary of mean serum concentrations of Efavaleukin alfa over time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2a: Maximum Observed Serum Concentration (Cmax) of Efavaleukin Alfa</measure>
    <time_frame>Day 1 (pre-dose) and weeks 2, 4, 6, 8, 10 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2a: Time to Maximum Observed Serum Concentration (Tmax) of Efavaleukin Alfa</measure>
    <time_frame>Day 1 (pre-dose) and weeks 2, 4, 6, 8, 10 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2a: Area Under the Concentration-time Curve (AUC) of Efavaleukin Alfa</measure>
    <time_frame>Day 1 (pre-dose) and weeks 2, 4, 6, 8, 10 and 12</time_frame>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Rheumatoid Arthritis RA</condition>
  <arm_group>
    <arm_group_label>Phase 1b: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo administered via subcutaneous injection for a total of up to 12 weeks. Participants received placebo in 1 of 2 dosing schedules (i.e. dosing schedule A [less frequent] or schedule B [more frequent]).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1b: Efavaleukin alfa Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A low dose of Efavaleukin alfa administered via subcutaneous injection using dosing schedule A (less frequent than schedule B) for a total of up to 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1b: Efavaleukin alfa Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A high dose of Efavaleukin alfa administered via subcutaneous injection using dosing schedule A (less frequent than schedule B) for a total of up to 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1b: Efavaleukin alfa Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A medium dose of Efavaleukin alfa administered via subcutaneous injection using dosing schedule B (more frequent than schedule A) for a total of up to 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1b: Efavaleukin alfa Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A medium/high dose of Efavaleukin alfa administered via subcutaneous injection using dosing schedule B (more frequent than schedule A) for a total of up to 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2a: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo administered via subcutaneous injection, depending on the recommended phase 2 dose (RP2D) and dosing schedule as determined in phase 1b, for a total of up to 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2a: Efavaleukin alfa</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Efavaleukin alfa administered via subcutaneous injection depending on the RP2D and dosing schedule determined in phase 1b, for up to a total of up to 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Efavaleukin alfa</intervention_name>
    <description>Efavaleukin alfa administered as a subcutaneous injection.</description>
    <arm_group_label>Phase 1b: Efavaleukin alfa Cohort 1</arm_group_label>
    <arm_group_label>Phase 1b: Efavaleukin alfa Cohort 2</arm_group_label>
    <arm_group_label>Phase 1b: Efavaleukin alfa Cohort 3</arm_group_label>
    <arm_group_label>Phase 1b: Efavaleukin alfa Cohort 4</arm_group_label>
    <arm_group_label>Phase 2a: Efavaleukin alfa</arm_group_label>
    <other_name>AMG 592</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo administered as a subcutaneous injection.</description>
    <arm_group_label>Phase 1b: Placebo</arm_group_label>
    <arm_group_label>Phase 2a: Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject has provided informed consent prior to initiation of any study specific&#xD;
             activities/procedures.&#xD;
&#xD;
          -  Age â‰¥ 18 to â‰¤ 70 years of age at screening.&#xD;
&#xD;
          -  A diagnosis of RA consistent with the 1987 or 2010 American College of Rheumatology&#xD;
             (ACR)/European League Against Rheumatism classification criteria.&#xD;
&#xD;
          -  Active RA defined as: Phase 1b: DAS-28-CRP &gt; 2.6 at screening. The 28-joint count&#xD;
             consists of the finger joints excluding the distal interphalangeal joints, the wrists,&#xD;
             elbows, shoulders, and knees. Phase 2a: â‰¥ 6 swollen joints (based on 66-joint count)&#xD;
             and â‰¥ 6 tender joints (based on 68-joint count) at screening and baseline. The distal&#xD;
             interphalangeal joint should be evaluated but not included in the total count to&#xD;
             determine eligibility. Additionally, C-reactive protein (CRP) must be greater than the&#xD;
             upper limit of normal (ULN) per the central laboratory at screening.&#xD;
&#xD;
          -  Receiving treatment with methotrexate for â‰¥ 12 weeks and on a stable dose â‰¥ 15 mg&#xD;
             weekly for â‰¥ 8 weeks prior to day 1. A lower methotrexate dose is acceptable (but no&#xD;
             lower than 10 mg weekly) if it is the highest tolerated dose and gastrointestinal or&#xD;
             hematologic toxicity at doses â‰¥ 15 mg weekly is documented by the investigator.&#xD;
&#xD;
          -  Receiving treatment with folic or folinic acid per investigator judgment or according&#xD;
             to local standard of care.&#xD;
&#xD;
          -  Phase 1b only: Subject may be receiving a stable dose of leflunomide, sulfasalazine,&#xD;
             hydroxychloroquine, minocycline in combination with methotrexate and the dose must be&#xD;
             stable for â‰¥ 8 weeks prior to day 1.&#xD;
&#xD;
          -  Subject may be receiving a stable dose of prednisone â‰¤ 10mg daily or other equivalent&#xD;
             corticosteroid dose and the dose must be stable for â‰¥ 2 weeks prior today 1.&#xD;
&#xD;
          -  Phase 1b only. Normal or clinically acceptable electrocardiogram (ECG) values (12-lead&#xD;
             reporting ventricular rate and PR, QRS, QT and QTc interval) at screening and baseline&#xD;
             based on opinion of the investigator.&#xD;
&#xD;
          -  Immunizations (tetanus, diphtheria, pertussis, seasonal influenza [during flu season],&#xD;
             and pneumococcal [polysaccharide] vaccinations) up to date per local standards as&#xD;
             determined by the investigator.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Class IV RA according to ACR revised response criteria&#xD;
&#xD;
          -  Diagnosis of Felty's Syndrome (RA, splenomegaly and granulocytopenia).&#xD;
&#xD;
          -  Prosthetic joint infection within 3 years of screening or native joint infection&#xD;
             within 1 year prior to screening.&#xD;
&#xD;
          -  Active infection (including chronic or localized infections) for which anti-infectives&#xD;
             were indicated within 4 weeks prior to day 1 OR presence of serious infection, defined&#xD;
             as requiring hospitalization or intravenous anti-infectives within 8 weeks prior to&#xD;
             day 1.&#xD;
&#xD;
          -  Known history of active tuberculosis.&#xD;
&#xD;
          -  Positive test for tuberculosis during screening defined as either: positive purified&#xD;
             protein derivative (PPD) (â‰¥ 5 mm of induration at 48 to 72 hours after test is placed)&#xD;
             OR positive Quantiferon test: a positive PPD and a history of Bacillus Calmette-GuÃ©rin&#xD;
             vaccination are allowed with a negative Quantiferon test and negative chest x ray; a&#xD;
             positive PPD test (without a history of Bacillus Calmette-GuÃ©rin vaccination) or a&#xD;
             positive or indeterminate Quantiferon test are allowed if they have ALL of the&#xD;
             following at screening: no symptoms per tuberculosis or sheet provided by Amgen;&#xD;
             document history of a completed course of adequate prophylaxis(completed treatment for&#xD;
             latent tuberculosis per local standard of care prior to the start of investigational&#xD;
             product); no known exposure to a case of active tuberculosis after most recent&#xD;
             prophylaxis; negative chest X-ray.&#xD;
&#xD;
          -  Positive for hepatitis B surface antigen, hepatitis B core antibody (confirmed by&#xD;
             hepatitis B deoxyribonucleic acid (DNA) polymerase chain reaction [PCR] test) or&#xD;
             detectable hepatitis C virus ribonucleic acid (RNA) by PCR (screening is generally&#xD;
             done by hepatitis C antibody [HepCAb], followed by hepatitis C virus RNA by PCR if&#xD;
             HepCAb is positive). A history of hepatitis B vaccination without history of hepatitis&#xD;
             B is allowed.&#xD;
&#xD;
          -  Phase 1b only: Positive for Human Immunodeficiency Virus (HIV) at screening or known&#xD;
             to be HIV positive. Phase 2a only: Known history of HIV&#xD;
&#xD;
          -  Phase 1b only: Positive drug or alcohol urine test for illicit drugs at screening.&#xD;
             Prescription medications detected by the drug test are allowed if they are being taken&#xD;
             under the direction of a physician.&#xD;
&#xD;
          -  Presence of one or more significant concurrent medical conditions per investigator&#xD;
             judgment, including but not limited to the following: poorly controlled diabetes or&#xD;
             hypertension; chronic kidney disease stage IIIb, IV, or V; symptomatic heart failure&#xD;
             (New York Heart Association class II, III, or IV); myocardial infarction or unstable&#xD;
             angina pectoris within the past 12 months prior to randomization; severe chronic&#xD;
             pulmonary disease (eg, requiring oxygen therapy); multiple sclerosis or any other&#xD;
             demyelinating disease; major chronic inflammatory disease or connective tissue disease&#xD;
             other than RA (eg, systemic lupus erythematosus with the exception of secondary&#xD;
             SjÃ¶gren's syndrome).&#xD;
&#xD;
          -  Malignancy except non-melanoma skin cancers, cervical or breast ductal carcinoma in&#xD;
             situ within the last 5 years.&#xD;
&#xD;
          -  History of alcohol or substance abuse within 6 months of screening&#xD;
&#xD;
          -  Phase 1b only: Current smoker, and/or use of any nicotine or tobacco containing&#xD;
             products within the last 6 months prior to day 1. These types of products include but&#xD;
             are not limited to: snuff, chewing tobacco, cigars, electronic cigarettes, cigarettes,&#xD;
             pipes, or nicotine patches.&#xD;
&#xD;
          -  Phase 1b only: Subject unwilling to limit alcohol consumption to â‰¤ 1 drink of alcohol&#xD;
             per day and â‰¤ 3 drinks per week for the duration of the study, where a drink is&#xD;
             equivalent to 12 ounces of regular beer, 8 to 9 ounces of malt liquor, 5 ounces of&#xD;
             wine, or 1.5 ounces of 80 proof distilled spirits. Phase 1b only: Unwilling or unable&#xD;
             to abstain from alcohol consumption within 48 hours prior to each visit (including&#xD;
             screening).&#xD;
&#xD;
          -  Subjects who have received intra-articular or systemic corticosteroid injections for&#xD;
             treatment of acute RA flare (not being part of a regular therapeutic regimen) within 4&#xD;
             weeks prior to screening.&#xD;
&#xD;
          -  Currently receiving or had treatment with cyclophosphamide, chlorambucil, nitrogen&#xD;
             mustard, or any other alkylating agent â‰¤ 6 months prior to day 1.&#xD;
&#xD;
          -  Prior treatment with more than a total of 3 therapies that include biologic disease&#xD;
             modifying anti-rheumatic drug (DMARDs) or oral synthetic DMARDs (such as tofacinitib,&#xD;
             baricitinib). Prior treatment consists of at least 4 doses of a given therapy where&#xD;
             the doses were given solely for treatment of RA disease. Prior therapies must not have&#xD;
             been used within the following time periods:&#xD;
&#xD;
               -  â‰¤ 4 weeks prior to day 1 for etanercept and anakinra&#xD;
&#xD;
               -  â‰¤ 6 months for rituximab&#xD;
&#xD;
               -  â‰¤ 2 weeks for oral janus kinase inhibitors&#xD;
&#xD;
               -  â‰¤ 9 weeks prior to day 1 for all therapies not listed above&#xD;
&#xD;
          -  Currently receiving or had treatment with any of the following â‰¤ 12 weeks prior to day&#xD;
             1:&#xD;
&#xD;
               -  azathioprine&#xD;
&#xD;
               -  cyclosporine&#xD;
&#xD;
               -  gold&#xD;
&#xD;
               -  mycophenolate mofetil&#xD;
&#xD;
               -  Prosorba column&#xD;
&#xD;
               -  Tacrolimus&#xD;
&#xD;
          -  Phase 2a only: Currently receiving or had treatment with leflunomide â‰¤ 12 weeks prior&#xD;
             to day 1 unless an active washout with cholestyramine has been performed.&#xD;
&#xD;
          -  Phase 2a only: Currently receiving or had treatment with any of the following â‰¤ 4&#xD;
             weeks prior to day 1:&#xD;
&#xD;
               -  hydroxychloroquine&#xD;
&#xD;
               -  sulfasalazine&#xD;
&#xD;
               -  minocycline&#xD;
&#xD;
               -  oral janus kinase inhibitor (eg, tofacitinib, baricitinib)&#xD;
&#xD;
               -  intra-articular, intramuscular or intravenous corticosteroids, including&#xD;
                  adrenocorticotropic hormone&#xD;
&#xD;
               -  intra-articular hyaluronic acid injections&#xD;
&#xD;
               -  live vaccines -- For Phase 2 only:&#xD;
&#xD;
          -  Unstable dose of non-steroidal anti-inflammatory drugs (NSAID), acetaminophen, and/or&#xD;
             analgesics which is taken on an unscheduled basis (ie, not daily or scheduled every&#xD;
             certain number of hours) and/or initiated &lt;4 weeks prior to day 1.&#xD;
&#xD;
          -  Received the following within 12 hours prior to screening or day 1:&#xD;
&#xD;
        acetaminophen, NSAIDs, tramadol, and/or any narcotic analgesics such as but not limited to&#xD;
        hydrocodone, codeine, tramadol, propoxyphene and/or oxycodone (unless in the form of&#xD;
        oxycontin). Subject has taken oxycontin within 24 hours prior to screening or day 1.&#xD;
&#xD;
          -  Phase 1b only: Received any herbal medicines (eg St John's wort),or non-vitamin&#xD;
             dietary supplements (eg, magnesium) with the exception of calcium within 4 weeks prior&#xD;
             to day 1.&#xD;
&#xD;
          -  Currently receiving treatment in another investigational device or drug study, or less&#xD;
             than 30 days since ending treatment on another investigational device or drug&#xD;
             study(ies). Other investigational procedures while participating in this study are&#xD;
             excluded.&#xD;
&#xD;
          -  Presence of laboratory abnormalities at screening including the following:&#xD;
&#xD;
               -  Aspartate aminotransferase (AST) or alanine amino transferase (ALT) at screening&#xD;
                  &gt; 1.5X upper limit of normal (ULN)&#xD;
&#xD;
               -  Serum total bilirubin (TBL) â‰¥ 1.5 mg/dL (â‰¥ 26 Î¼mol/L)&#xD;
&#xD;
               -  Hemoglobin â‰¤ 10.5 g/dL(â‰¤105 g/L)&#xD;
&#xD;
               -  Platelet count &lt; 100,000/mm^3 (&lt;100 x 10^9/L)&#xD;
&#xD;
               -  White blood cell count &lt; 2,500 cells/mm^3 (2.5 x 10^9/L)&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) &lt; 1,000/mm^3 (1.0 x 10^9/L)&#xD;
&#xD;
               -  Calculated glomerular filtration rate of â‰¤ 50 mL/min/1.73 m^2 using the&#xD;
                  Modification of Diet in Renal Disease (MDRD) formula&#xD;
&#xD;
          -  Any other laboratory abnormality, which, in the opinion of the investigator, poses a&#xD;
             safety risk, will prevent the subject from completing the study, will interfere with&#xD;
             the interpretation of the study results, or might cause the study to be detrimental to&#xD;
             the subject.&#xD;
&#xD;
          -  Female subject is pregnant or breastfeeding or planning to become pregnant or&#xD;
             breastfeed during treatment and for an additional 6 weeks after the last dose of&#xD;
             investigational product.&#xD;
&#xD;
          -  Females of child-bearing potential with a positive pregnancy test (assessed by a serum&#xD;
             pregnancy test at screening and a urine pregnancy test at baseline).&#xD;
&#xD;
          -  Female subjects of childbearing potential unwilling to use 1 highly effective method&#xD;
             of contraception during treatment and for an additional 6 weeks after the last dose of&#xD;
             investigational product.&#xD;
&#xD;
          -  Subject has known sensitivity to any of the products or components to be administered&#xD;
             during dosing.&#xD;
&#xD;
          -  Subject likely to not be available to complete all protocol-required study visits or&#xD;
             procedures, and/or to comply with all required study procedures (eg, Clinical Outcome&#xD;
             Assessments [COAs]) to the best of the subject and investigator's knowledge.&#xD;
&#xD;
          -  History or evidence of any other clinically significant disorder, condition or disease&#xD;
             (with the exception of those outlined above) that, in the opinion of the investigator&#xD;
             or Amgen physician, if consulted, would pose a risk to subject safety or interfere&#xD;
             with the study evaluation, procedures or completion&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Anniston</city>
        <state>Alabama</state>
        <zip>36207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lansing</city>
        <state>Michigan</state>
        <zip>48910</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Duncansville</city>
        <state>Pennsylvania</state>
        <zip>16635</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sofia</city>
        <zip>1612</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Frankfurt am Main</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jozefow</city>
        <zip>05-410</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Krakow</city>
        <zip>30-348</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Poznan</city>
        <zip>60-848</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Stalowa Wola</city>
        <zip>37-450</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Swidnik</city>
        <zip>21-040</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wroclaw</city>
        <zip>51-128</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>A CoruÃ±a</city>
        <state>Galicia</state>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Germany</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>January 3, 2018</study_first_submitted>
  <study_first_submitted_qc>January 18, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 25, 2018</study_first_posted>
  <results_first_submitted>May 11, 2021</results_first_submitted>
  <results_first_submitted_qc>May 11, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">June 4, 2021</results_first_posted>
  <disposition_first_submitted>October 29, 2020</disposition_first_submitted>
  <disposition_first_submitted_qc>October 29, 2020</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">November 2, 2020</disposition_first_posted>
  <last_update_submitted>June 10, 2021</last_update_submitted>
  <last_update_submitted_qc>June 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.</ipd_time_frame>
    <ipd_access_criteria>Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the link below.</ipd_access_criteria>
    <ipd_url>https://www.amgen.com/datasharing</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 6, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/56/NCT03410056/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 7, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/56/NCT03410056/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants in phase 1b were to be enrolled into 1 of 4 planned dosing cohorts and randomized in a 3:1 ratio to receive Efavaleukin alfa or placebo according to 1 of 2 dosing schedules; A (less frequent) and B (more frequent).</recruitment_details>
      <pre_assignment_details>Enrollment of the phase 1b part of this study was stopped as of 30 September 2019, due to data that suggested that there is not sufficient benefit-risk for the use of Efavaleukin alfa plus standard of care therapy in this study population. The study was terminated prior to the enrollment of any participants into phase 1b Cohort 4 and phase 2a cohorts.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Phase 1b: Placebo</title>
          <description>Matching placebo administered via subcutaneous injection for a total of up to 12 weeks. Participants received placebo in 1 of 2 dosing schedules (i.e. dosing schedule A [less frequent] or schedule B [more frequent]).</description>
        </group>
        <group group_id="P2">
          <title>Phase 1b: Efavaleukin Alfa Cohort 1</title>
          <description>A low dose of Efavaleukin alfa administered via subcutaneous injection using dosing schedule A (less frequent than schedule B) for a total of up to 12 weeks.</description>
        </group>
        <group group_id="P3">
          <title>Phase 1b: Efavaleukin Alfa Cohort 2</title>
          <description>A high dose of Efavaleukin alfa administered via subcutaneous injection using dosing schedule A (less frequent than schedule B) for a total of up to 12 weeks.</description>
        </group>
        <group group_id="P4">
          <title>Phase 1b: Efavaleukin Alfa Cohort 3</title>
          <description>A medium dose of Efavaleukin alfa administered via subcutaneous injection using dosing schedule B (more frequent than schedule A) for a total of up to 12 weeks.</description>
        </group>
        <group group_id="P5">
          <title>Phase 1b: Efavaleukin Alfa Cohort 4</title>
          <description>A medium/high dose of Efavaleukin alfa administered via subcutaneous injection using dosing schedule B (more frequent than schedule A) for a total of up to 12 weeks.&#xD;
No participants were enrolled into this cohort as the study was terminated prior to initiation of Cohort 4.</description>
        </group>
        <group group_id="P6">
          <title>Phase 2a: Placebo</title>
          <description>Matching placebo administered via subcutaneous injection, depending on the recommended phase 2 dose (RP2D) and dosing schedule as determined in phase 1b, for a total of up to 12 weeks.&#xD;
The study was terminated prior to the start of phase 2a and no participants were enrolled.</description>
        </group>
        <group group_id="P7">
          <title>Phase 2a: Efavaleukin Alfa</title>
          <description>Efavaleukin alfa administered via subcutaneous injection depending on the RP2D and dosing schedule determined in phase 1b, for up to a total of up to 12 weeks.&#xD;
The study was terminated prior to the start of phase 2a and no participants were enrolled.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="11"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Treatment</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="11"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Decision by Sponsor</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The safety analysis set: All participants who received at least 1 dose of investigational product.&#xD;
Only cohorts with enrolled participants are included in the baseline population.</population>
      <group_list>
        <group group_id="B1">
          <title>Phase 1b: Placebo</title>
          <description>Matching placebo administered via subcutaneous injection for a total of up to 12 weeks. Participants received placebo in 1 of 2 dosing schedules (i.e. dosing schedule A [less frequent] or schedule B [more frequent]).</description>
        </group>
        <group group_id="B2">
          <title>Phase 1b: Efavaleukin Alfa Cohort 1</title>
          <description>A low dose of Efavaleukin alfa administered via subcutaneous injection using dosing schedule A (less frequent than schedule B) for a total of up to 12 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Phase 1b: Efavaleukin Alfa Cohort 2</title>
          <description>A high dose of Efavaleukin alfa administered via subcutaneous injection using dosing schedule A (less frequent than schedule B) for a total of up to 12 weeks.</description>
        </group>
        <group group_id="B4">
          <title>Phase 1b: Efavaleukin Alfa Cohort 3</title>
          <description>A medium dose of Efavaleukin alfa administered via subcutaneous injection using dosing schedule B (more frequent than schedule A) for a total of up to 12 weeks.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="11"/>
            <count group_id="B4" value="11"/>
            <count group_id="B5" value="36"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46.4" spread="12.1"/>
                    <measurement group_id="B2" value="57.8" spread="8.4"/>
                    <measurement group_id="B3" value="53.1" spread="10.7"/>
                    <measurement group_id="B4" value="51.4" spread="15.3"/>
                    <measurement group_id="B5" value="51.9" spread="12.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="32"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Phase 1b: Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE)</title>
        <description>TEAEs were events with an onset after the administration of the first dose of study treatment.&#xD;
TEAEs were graded using the Common Terminology Criteria for Adverse Events (CTCAE).&#xD;
Grade 2 Moderate; minimal, local or noninvasive intervention indicated; limited age appropriate instrumental activities of daily life (ADL).&#xD;
Grade 3 Severe or medically significant but not immediately life-threatening; hospitalization or prolonged hospitalization indicated; disabling; limited self care ADL.&#xD;
Grade 4 Life-threatening consequences; urgent interventions indicated.&#xD;
Serious adverse events (SAEs) were defined as meeting at least 1 of the following criteria:&#xD;
Results in death (fatal)&#xD;
Immediately life-threatening&#xD;
Requires in-patient hospitalization or prolongation of existing hospitalization&#xD;
Results in persistent or significant disability/incapacity&#xD;
Is a congenital anomaly/birth defect&#xD;
Other medically important serious event</description>
        <time_frame>Day 1 up to end of study, maximum of 18 weeks (12-weeks double-blind treatment, 6-weeks safety follow-up)</time_frame>
        <population>The safety analysis set: All participants who received at least 1 dose of investigational product. Only cohorts with enrolled participants are included.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 1b: Placebo</title>
            <description>Matching placebo administered via subcutaneous injection for a total of up to 12 weeks. Participants received placebo in 1 of 2 dosing schedules (i.e. dosing schedule A [less frequent] or schedule B [more frequent]).</description>
          </group>
          <group group_id="O2">
            <title>Phase 1b: Efavaleukin Alfa Cohort 1</title>
            <description>A low dose of Efavaleukin alfa administered via subcutaneous injection using dosing schedule A (less frequent than schedule B) for a total of up to 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Phase 1b: Efavaleukin Alfa Cohort 2</title>
            <description>A high dose of Efavaleukin alfa administered via subcutaneous injection using dosing schedule A (less frequent than schedule B) for a total of up to 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Phase 1b: Efavaleukin Alfa Cohort 3</title>
            <description>A medium dose of Efavaleukin alfa administered via subcutaneous injection using dosing schedule B (more frequent than schedule A) for a total of up to 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 1b: Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE)</title>
          <description>TEAEs were events with an onset after the administration of the first dose of study treatment.&#xD;
TEAEs were graded using the Common Terminology Criteria for Adverse Events (CTCAE).&#xD;
Grade 2 Moderate; minimal, local or noninvasive intervention indicated; limited age appropriate instrumental activities of daily life (ADL).&#xD;
Grade 3 Severe or medically significant but not immediately life-threatening; hospitalization or prolonged hospitalization indicated; disabling; limited self care ADL.&#xD;
Grade 4 Life-threatening consequences; urgent interventions indicated.&#xD;
Serious adverse events (SAEs) were defined as meeting at least 1 of the following criteria:&#xD;
Results in death (fatal)&#xD;
Immediately life-threatening&#xD;
Requires in-patient hospitalization or prolongation of existing hospitalization&#xD;
Results in persistent or significant disability/incapacity&#xD;
Is a congenital anomaly/birth defect&#xD;
Other medically important serious event</description>
          <population>The safety analysis set: All participants who received at least 1 dose of investigational product. Only cohorts with enrolled participants are included.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade â‰¥ 2 TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade â‰¥ 3 TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade â‰¥ 4 TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAEs leading to discontinuation of study treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Life-threatening TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatal TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Phase 1b: Number of Participants Who Experienced a Clinically Significant Change in Vital Signs</title>
        <description>Any changes in systolic/diastolic blood pressure, heart rate, respiratory rate, and temperature that were deemed as clinically significant by the Investigator were reported.</description>
        <time_frame>Baseline up to end of study, maximum of 18 weeks (12-weeks double-blind treatment, 6-weeks safety follow-up)</time_frame>
        <population>The safety analysis set: All participants who received at least 1 dose of investigational product. Only cohorts with enrolled participants are included.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 1b: Placebo</title>
            <description>Matching placebo administered via subcutaneous injection for a total of up to 12 weeks. Participants received placebo in 1 of 2 dosing schedules (i.e. dosing schedule A [less frequent] or schedule B [more frequent]).</description>
          </group>
          <group group_id="O2">
            <title>Phase 1b: Efavaleukin Alfa Cohort 1</title>
            <description>A low dose of Efavaleukin alfa administered via subcutaneous injection using dosing schedule A (less frequent than schedule B) for a total of up to 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Phase 1b: Efavaleukin Alfa Cohort 2</title>
            <description>A high dose of Efavaleukin alfa administered via subcutaneous injection using dosing schedule A (less frequent than schedule B) for a total of up to 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Phase 1b: Efavaleukin Alfa Cohort 3</title>
            <description>A medium dose of Efavaleukin alfa administered via subcutaneous injection using dosing schedule B (more frequent than schedule A) for a total of up to 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 1b: Number of Participants Who Experienced a Clinically Significant Change in Vital Signs</title>
          <description>Any changes in systolic/diastolic blood pressure, heart rate, respiratory rate, and temperature that were deemed as clinically significant by the Investigator were reported.</description>
          <population>The safety analysis set: All participants who received at least 1 dose of investigational product. Only cohorts with enrolled participants are included.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Phase 1b: Number of Participants Who Experienced a Clinically Significant Change in Laboratory Safety Tests</title>
        <description>Laboratory safety tests included chemistry and hematology parameters. Clinically significant laboratory safety tests were any events assessed as CTCAE Grade â‰¥3 at any post-baseline visit.&#xD;
Grade 3 Severe or medically significant but not immediately life-threatening; hospitalization or prolonged hospitalization indicated; disabling; limited self care ADL.&#xD;
Grade 4 Life-threatening consequences; urgent interventions indicated.</description>
        <time_frame>Baseline up to end of study, maximum of 18 weeks (12-weeks double-blind treatment, 6-weeks safety follow-up)</time_frame>
        <population>The safety analysis set: All participants who received at least 1 dose of investigational product. Only cohorts with enrolled participants are included.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 1b: Placebo</title>
            <description>Matching placebo administered via subcutaneous injection for a total of up to 12 weeks. Participants received placebo in 1 of 2 dosing schedules (i.e. dosing schedule A [less frequent] or schedule B [more frequent]).</description>
          </group>
          <group group_id="O2">
            <title>Phase 1b: Efavaleukin Alfa Cohort 1</title>
            <description>A low dose of Efavaleukin alfa administered via subcutaneous injection using dosing schedule A (less frequent than schedule B) for a total of up to 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Phase 1b: Efavaleukin Alfa Cohort 2</title>
            <description>A high dose of Efavaleukin alfa administered via subcutaneous injection using dosing schedule A (less frequent than schedule B) for a total of up to 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Phase 1b: Efavaleukin Alfa Cohort 3</title>
            <description>A medium dose of Efavaleukin alfa administered via subcutaneous injection using dosing schedule B (more frequent than schedule A) for a total of up to 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 1b: Number of Participants Who Experienced a Clinically Significant Change in Laboratory Safety Tests</title>
          <description>Laboratory safety tests included chemistry and hematology parameters. Clinically significant laboratory safety tests were any events assessed as CTCAE Grade â‰¥3 at any post-baseline visit.&#xD;
Grade 3 Severe or medically significant but not immediately life-threatening; hospitalization or prolonged hospitalization indicated; disabling; limited self care ADL.&#xD;
Grade 4 Life-threatening consequences; urgent interventions indicated.</description>
          <population>The safety analysis set: All participants who received at least 1 dose of investigational product. Only cohorts with enrolled participants are included.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Phase 1b: Number of Participants Who Experienced a Clinically Significant Change in Electrocardiograms (ECGs)</title>
        <description>Any changes in ECG parameters that were deemed clinically significant by the investigator were reported.</description>
        <time_frame>Baseline up to end of treatment maximum of 12 weeks</time_frame>
        <population>The safety analysis set: All participants who received at least 1 dose of investigational product. Only cohorts with enrolled participants are included.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 1b: Placebo</title>
            <description>Matching placebo administered via subcutaneous injection for a total of up to 12 weeks. Participants received placebo in 1 of 2 dosing schedules (i.e. dosing schedule A [less frequent] or schedule B [more frequent]).</description>
          </group>
          <group group_id="O2">
            <title>Phase 1b: Efavaleukin Alfa Cohort 1</title>
            <description>A low dose of Efavaleukin alfa administered via subcutaneous injection using dosing schedule A (less frequent than schedule B) for a total of up to 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Phase 1b: Efavaleukin Alfa Cohort 2</title>
            <description>A high dose of Efavaleukin alfa administered via subcutaneous injection using dosing schedule A (less frequent than schedule B) for a total of up to 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Phase 1b: Efavaleukin Alfa Cohort 3</title>
            <description>A medium dose of Efavaleukin alfa administered via subcutaneous injection using dosing schedule B (more frequent than schedule A) for a total of up to 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 1b: Number of Participants Who Experienced a Clinically Significant Change in Electrocardiograms (ECGs)</title>
          <description>Any changes in ECG parameters that were deemed clinically significant by the investigator were reported.</description>
          <population>The safety analysis set: All participants who received at least 1 dose of investigational product. Only cohorts with enrolled participants are included.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Phase 2a: Number of Participants Who Achieved an American College of Rheumatology 20 Percent Improvement Criteria (ACR 20) at Week 12</title>
        <description>ACR 20 response defined as at least 20 percent improvement from baseline in both tender and swollen joint counts, and a 20 percent improvement or more in at least 3 of the following 5 criteria:&#xD;
physician global assessment of disease activity (PGA)&#xD;
subject global assessment of disease activity (SGA)&#xD;
patient global assessment of joint pain&#xD;
subject self-assessment of disability (HAQ-DI)&#xD;
C-Reactive Protein (CRP)</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>No data is available for phase 2a. Study was terminated prior to any participants enrolling in phase 2a.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 2a: Placebo</title>
            <description>Matching placebo administered via subcutaneous injection, depending on the recommended phase 2 dose (RP2D) and dosing schedule as determined in phase 1b, for a total of up to 12 weeks.&#xD;
The study was terminated prior to the start of phase 2a and no participants were enrolled.</description>
          </group>
          <group group_id="O2">
            <title>Phase 2a: Efavaleukin Alfa</title>
            <description>Efavaleukin alfa administered via subcutaneous injection depending on the RP2D and dosing schedule determined in phase 1b, for up to a total of up to 12 weeks.&#xD;
The study was terminated prior to the start of phase 2a and no participants were enrolled.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 2a: Number of Participants Who Achieved an American College of Rheumatology 20 Percent Improvement Criteria (ACR 20) at Week 12</title>
          <description>ACR 20 response defined as at least 20 percent improvement from baseline in both tender and swollen joint counts, and a 20 percent improvement or more in at least 3 of the following 5 criteria:&#xD;
physician global assessment of disease activity (PGA)&#xD;
subject global assessment of disease activity (SGA)&#xD;
patient global assessment of joint pain&#xD;
subject self-assessment of disability (HAQ-DI)&#xD;
C-Reactive Protein (CRP)</description>
          <population>No data is available for phase 2a. Study was terminated prior to any participants enrolling in phase 2a.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 1b: Efavaleukin Alfa Serum Concentrations</title>
        <description>A summary of mean serum concentrations of Efavaleukin alfa over time is presented. Any results below the lower limit of quantification were set to 0.00.</description>
        <time_frame>Day 1 (pre-dose), 6 and 12 hours post-dose, and days 2, 3, 4, 8, 11, 15, 22, 29, 36, 43, 50, 57, 64, 71, 78, and Day 85 (pre-dose), 6 and 12 hours post-dose and days 86, 87, 88, 92, 99, 113 and 127</time_frame>
        <population>The pharmacokinetic (PK) analysis set: All participants who received at least one dose of Efavaleukin alfa and had at least one quantifiable PK sample collected. Only participants with PK data available for analysis are presented. Only cohorts with enrolled participants are included.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 1b: Efavaleukin Alfa Cohort 1</title>
            <description>A low dose of Efavaleukin alfa administered via subcutaneous injection using dosing schedule A (less frequent than schedule B) for a total of up to 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Phase 1b: Efavaleukin Alfa Cohort 2</title>
            <description>A high dose of Efavaleukin alfa administered via subcutaneous injection using dosing schedule A (less frequent than schedule B) for a total of up to 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Phase 1b: Efavaleukin Alfa Cohort 3</title>
            <description>A medium dose of Efavaleukin alfa administered via subcutaneous injection using dosing schedule B (more frequent than schedule A) for a total of up to 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 1b: Efavaleukin Alfa Serum Concentrations</title>
          <description>A summary of mean serum concentrations of Efavaleukin alfa over time is presented. Any results below the lower limit of quantification were set to 0.00.</description>
          <population>The pharmacokinetic (PK) analysis set: All participants who received at least one dose of Efavaleukin alfa and had at least one quantifiable PK sample collected. Only participants with PK data available for analysis are presented. Only cohorts with enrolled participants are included.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 (pre-dose)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.00"/>
                    <measurement group_id="O2" value="0.0" spread="0.00"/>
                    <measurement group_id="O3" value="0.00" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 (6 hours post-dose)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.35" spread="0.795"/>
                    <measurement group_id="O2" value="7.67" spread="8.01"/>
                    <measurement group_id="O3" value="2.13" spread="2.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 (12 hours post-dose)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.43" spread="0.867"/>
                    <measurement group_id="O2" value="14.6" spread="12.1"/>
                    <measurement group_id="O3" value="4.09" spread="4.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.59" spread="0.875"/>
                    <measurement group_id="O2" value="22.0" spread="11.5"/>
                    <measurement group_id="O3" value="5.44" spread="5.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.70" spread="0.850"/>
                    <measurement group_id="O2" value="18.6" spread="9.16"/>
                    <measurement group_id="O3" value="3.65" spread="3.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.727" spread="0.277"/>
                    <measurement group_id="O2" value="7.65" spread="5.85"/>
                    <measurement group_id="O3" value="2.36" spread="2.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0555" spread="0.0924"/>
                    <measurement group_id="O2" value="0.108" spread="0.146"/>
                    <measurement group_id="O3" value="0.0284" spread="0.0624"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 11</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0230" spread="0.0514"/>
                    <measurement group_id="O2" value="0.0115" spread="0.0364"/>
                    <measurement group_id="O3" value="0.930" spread="0.780"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.00"/>
                    <measurement group_id="O2" value="0.00" spread="0.00"/>
                    <measurement group_id="O3" value="0.107" spread="0.150"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0830" spread="0.144"/>
                    <measurement group_id="O2" value="0.0703" spread="0.112"/>
                    <measurement group_id="O3" value="0.235" spread="0.373"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.00"/>
                    <measurement group_id="O2" value="0.00" spread="0.00"/>
                    <measurement group_id="O3" value="0.217" spread="0.344"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0644" spread="0.144"/>
                    <measurement group_id="O2" value="0.102" spread="0.203"/>
                    <measurement group_id="O3" value="0.239" spread="0.425"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 43</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.00"/>
                    <measurement group_id="O2" value="0.00" spread="0.00"/>
                    <measurement group_id="O3" value="0.104" spread="0.275"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 50</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.205" spread="0.304"/>
                    <measurement group_id="O2" value="0.105" spread="0.210"/>
                    <measurement group_id="O3" value="0.122" spread="0.322"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 57</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0368" spread="0.0735"/>
                    <measurement group_id="O2" value="0.00" spread="0.00"/>
                    <measurement group_id="O3" value="0.0886" spread="0.234"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 64</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.336" spread="NA">Insufficient samples were collected to assess SD.</measurement>
                    <measurement group_id="O2" value="0.212" spread="0.424"/>
                    <measurement group_id="O3" value="0.0294" spread="0.0657"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 71</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0635" spread="NA">Insufficient samples were collected to assess SD.</measurement>
                    <measurement group_id="O2" value="0.00" spread="0.00"/>
                    <measurement group_id="O3" value="0.00" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 78</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.154" spread="0.267"/>
                    <measurement group_id="O2" value="0.355" spread="0.614"/>
                    <measurement group_id="O3" value="0.0508" spread="0.0819"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 85 (pre-dose)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.00"/>
                    <measurement group_id="O2" value="0.00" spread="0.00"/>
                    <measurement group_id="O3" value="0.0578" spread="0.0958"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 85 (6 hours post-dose)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.41" spread="1.56"/>
                    <measurement group_id="O2" value="5.91" spread="NA">Insufficient samples were collected to assess SD.</measurement>
                    <measurement group_id="O3" value="1.92" spread="2.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 85 (12 hours post-dose)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.00" spread="2.05"/>
                    <measurement group_id="O2" value="12.9" spread="NA">Insufficient samples were collected to assess SD.</measurement>
                    <measurement group_id="O3" value="2.92" spread="4.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 86</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.60" spread="2.07"/>
                    <measurement group_id="O2" value="12.3" spread="NA">Insufficient samples were collected to assess SD.</measurement>
                    <measurement group_id="O3" value="2.97" spread="4.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 87</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.10" spread="1.15"/>
                    <measurement group_id="O2" value="4.39" spread="NA">Insufficient samples were collected to assess SD.</measurement>
                    <measurement group_id="O3" value="1.87" spread="2.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 88</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.48" spread="0.623"/>
                    <measurement group_id="O2" value="1.01" spread="NA">Insufficient samples were collected to assess SD.</measurement>
                    <measurement group_id="O3" value="0.903" spread="1.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 92</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.113" spread="NA">Insufficient samples were collected to assess SD.</measurement>
                    <measurement group_id="O2" value="0.00" spread="NA">Insufficient samples were collected to assess SD.</measurement>
                    <measurement group_id="O3" value="0.0953" spread="0.115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 99</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.00"/>
                    <measurement group_id="O2" value="0.00" spread="NA">Insufficient samples were collected to assess SD.</measurement>
                    <measurement group_id="O3" value="0.110" spread="0.268"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 113</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.00"/>
                    <measurement group_id="O2" value="0.00" spread="NA">Insufficient samples were collected to assess SD.</measurement>
                    <measurement group_id="O3" value="0.00" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 127</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.00"/>
                    <measurement group_id="O2" value="0.00" spread="NA">Insufficient samples were collected to assess SD.</measurement>
                    <measurement group_id="O3" value="0.00" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 1b: Maximum Observed Serum Concentration (Cmax) of Efavaleukin Alfa</title>
        <time_frame>Day 1 (pre-dose) and 6 to 48 hours post-dose, and days 4, 8, 11, 15, 22, 29, 36, 43, 50, 57, 64, 71, 78, Day 85 (pre-dose) and 6 to 72 hours post-dose, and days 92, 99, 113 and 127</time_frame>
        <population>The PK analysis set: All participants who received at least one dose of Efavaleukin alfa and had at least one quantifiable PK sample collected. Only participants with PK data available for analysis are presented. Only cohorts with enrolled participants are included.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 1b: Efavaleukin Alfa Cohort 1</title>
            <description>A low dose of Efavaleukin alfa administered via subcutaneous injection using dosing schedule A (less frequent than schedule B) for a total of up to 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Phase 1b: Efavaleukin Alfa Cohort 2</title>
            <description>A high dose of Efavaleukin alfa administered via subcutaneous injection using dosing schedule A (less frequent than schedule B) for a total of up to 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Phase 1b: Efavaleukin Alfa Cohort 3</title>
            <description>A medium dose of Efavaleukin alfa administered via subcutaneous injection using dosing schedule B (more frequent than schedule A) for a total of up to 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 1b: Maximum Observed Serum Concentration (Cmax) of Efavaleukin Alfa</title>
          <population>The PK analysis set: All participants who received at least one dose of Efavaleukin alfa and had at least one quantifiable PK sample collected. Only participants with PK data available for analysis are presented. Only cohorts with enrolled participants are included.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>First dose (Day 1)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.66" spread="0.852"/>
                    <measurement group_id="O2" value="23.0" spread="11.2"/>
                    <measurement group_id="O3" value="5.71" spread="5.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Last dose (Day 85)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.00" spread="2.05"/>
                    <measurement group_id="O2" value="NA" spread="NA">Insufficient samples were collected to assess mean Cmax.</measurement>
                    <measurement group_id="O3" value="3.22" spread="4.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 1b: Time to Maximum Observed Serum Concentration (Tmax) of Efavaleukin Alfa</title>
        <time_frame>Day 1 (pre-dose) and 6 to 48 hours post-dose, and days 4, 8, 11, 15, 22, 29, 36, 43, 50, 57, 64, 71, 78, Day 85 (pre-dose) and 6 to 72 hours post-dose, and days 92, 99, 113 and 127</time_frame>
        <population>The PK analysis set: All participants who received at least one dose of Efavaleukin alfa and had at least one quantifiable PK sample collected. Only participants with PK data available for analysis are presented. Only cohorts with enrolled participants are included.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 1b: Efavaleukin Alfa Cohort 1</title>
            <description>A low dose of Efavaleukin alfa administered via subcutaneous injection using dosing schedule A (less frequent than schedule B) for a total of up to 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Phase 1b: Efavaleukin Alfa Cohort 2</title>
            <description>A high dose of Efavaleukin alfa administered via subcutaneous injection using dosing schedule A (less frequent than schedule B) for a total of up to 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Phase 1b: Efavaleukin Alfa Cohort 3</title>
            <description>A medium dose of Efavaleukin alfa administered via subcutaneous injection using dosing schedule B (more frequent than schedule A) for a total of up to 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 1b: Time to Maximum Observed Serum Concentration (Tmax) of Efavaleukin Alfa</title>
          <population>The PK analysis set: All participants who received at least one dose of Efavaleukin alfa and had at least one quantifiable PK sample collected. Only participants with PK data available for analysis are presented. Only cohorts with enrolled participants are included.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>First dose (Day 1)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18" lower_limit="12" upper_limit="24"/>
                    <measurement group_id="O2" value="24" lower_limit="24" upper_limit="48"/>
                    <measurement group_id="O3" value="24" lower_limit="12" upper_limit="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Last dose (Day 85)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12" lower_limit="12" upper_limit="12"/>
                    <measurement group_id="O2" value="30" lower_limit="12" upper_limit="48"/>
                    <measurement group_id="O3" value="12" lower_limit="6.0" upper_limit="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 1b: Area Under the Concentration-time Curve From Time 0 to 14 Days (AUC0-14) Post Dose</title>
        <description>AUC0-14 was only assessed for the participants who received Efavaleukin alfa using dosing schedule A.</description>
        <time_frame>Day 1 (pre-dose) and 6 to 48 hours post-dose, and days 4, 8, 11 and 15, Day 85 (pre-dose) and 6 to 72 hours post-dose, and days 92 and 99</time_frame>
        <population>The PK analysis set: All participants who received at least one dose of Efavaleukin alfa and had at least one quantifiable PK sample collected. Only participants with PK data available for analysis are presented. Only cohorts with enrolled participants are included.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 1b: Efavaleukin Alfa Cohort 1</title>
            <description>A low dose of Efavaleukin alfa administered via subcutaneous injection using dosing schedule A (less frequent than schedule B) for a total of up to 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Phase 1b: Efavaleukin Alfa Cohort 2</title>
            <description>A high dose of Efavaleukin alfa administered via subcutaneous injection using dosing schedule A (less frequent than schedule B) for a total of up to 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 1b: Area Under the Concentration-time Curve From Time 0 to 14 Days (AUC0-14) Post Dose</title>
          <description>AUC0-14 was only assessed for the participants who received Efavaleukin alfa using dosing schedule A.</description>
          <population>The PK analysis set: All participants who received at least one dose of Efavaleukin alfa and had at least one quantifiable PK sample collected. Only participants with PK data available for analysis are presented. Only cohorts with enrolled participants are included.</population>
          <units>hr*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>First dose (Day 1)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="167" spread="60.9"/>
                    <measurement group_id="O2" value="1570" spread="859"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Last dose (Day 85)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="282" spread="207"/>
                    <measurement group_id="O2" value="NA" spread="NA">Insufficient samples were collected to assess AUC0-14</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 1b: Area Under the Concentration-time Curve From Time 0 to 7 Days (AUC0-7) Post Dose</title>
        <description>AUC0-7 was only assessed for the participants who received Efavaleukin alfa using dosing schedule B.</description>
        <time_frame>Day 1 (pre-dose) and 6 to 48 hours post-dose, and days 4 and 8, Day 85 (pre-dose) and 6 to 72 hours post-dose, and Day 92</time_frame>
        <population>The PK analysis set: All participants who received at least one dose of Efavaleukin alfa and had at least one quantifiable PK sample collected. Only participants with PK data available for analysis are presented. Only cohorts with enrolled participants are included.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 1b: Efavaleukin Alfa Cohort 3</title>
            <description>A medium dose of Efavaleukin alfa administered via subcutaneous injection using dosing schedule B (more frequent than schedule A) for a total of up to 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 1b: Area Under the Concentration-time Curve From Time 0 to 7 Days (AUC0-7) Post Dose</title>
          <description>AUC0-7 was only assessed for the participants who received Efavaleukin alfa using dosing schedule B.</description>
          <population>The PK analysis set: All participants who received at least one dose of Efavaleukin alfa and had at least one quantifiable PK sample collected. Only participants with PK data available for analysis are presented. Only cohorts with enrolled participants are included.</population>
          <units>hr*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>First dose (Day 1)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="315" spread="239"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Last dose (Day 85)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="195" spread="264"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 1b: Number of Participants With Anti-Efavaleukin Alfa Binding Antibodies and Anti-Interleukin (IL-2) Binding Antibodies</title>
        <description>Number of participants who tested positive for anti-Efavaleukin alfa binding antibodies and number of those participants who cross-reacted with native human IL-2 (i.e. with anti-IL-2 binding antibodies) are reported.</description>
        <time_frame>Baseline up to end of study, maximum of 18 weeks (12-weeks double-blind treatment, 6-weeks safety follow-up)</time_frame>
        <population>All participants who received at least 1 dose of investigational product and had a baseline and at least 1 post-baseline result. Only participants who tested positive for anti-Efavaleukin alfa antibodies were analyzed for presence of anti-IL2 binding antibodies. Only cohorts with enrolled participants are included.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 1b: Placebo</title>
            <description>Matching placebo administered via subcutaneous injection for a total of up to 12 weeks. Participants received placebo in 1 of 2 dosing schedules (i.e. dosing schedule A [less frequent] or schedule B [more frequent]).</description>
          </group>
          <group group_id="O2">
            <title>Phase 1b: Efavaleukin Alfa Cohort 1</title>
            <description>A low dose of Efavaleukin alfa administered via subcutaneous injection using dosing schedule A (less frequent than schedule B) for a total of up to 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Phase 1b: Efavaleukin Alfa Cohort 2</title>
            <description>A high dose of Efavaleukin alfa administered via subcutaneous injection using dosing schedule A (less frequent than schedule B) for a total of up to 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Phase 1b: Efavaleukin Alfa Cohort 3</title>
            <description>A medium dose of Efavaleukin alfa administered via subcutaneous injection using dosing schedule B (more frequent than schedule A) for a total of up to 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 1b: Number of Participants With Anti-Efavaleukin Alfa Binding Antibodies and Anti-Interleukin (IL-2) Binding Antibodies</title>
          <description>Number of participants who tested positive for anti-Efavaleukin alfa binding antibodies and number of those participants who cross-reacted with native human IL-2 (i.e. with anti-IL-2 binding antibodies) are reported.</description>
          <population>All participants who received at least 1 dose of investigational product and had a baseline and at least 1 post-baseline result. Only participants who tested positive for anti-Efavaleukin alfa antibodies were analyzed for presence of anti-IL2 binding antibodies. Only cohorts with enrolled participants are included.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Binding anti-AMG 592 antibody positive post-baseline with a negative or no result at baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Binding anti-IL2 antibody positive post-baseline with a negative or no result at baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 1b: Number of Participants With Anti-Efavaleukin Alfa Neutralizing Antibodies and Anti-IL-2 Neutralizing Antibodies</title>
        <description>The number of participants who tested positive for anti-Efavaleukin alfa neutralizing antibodies and number of participants with anti-IL2 neutralizing antibodies who tested negative or no result at baseline are reported.</description>
        <time_frame>Baseline up to end of study, maximum of 18 weeks (12-weeks double-blind treatment, 6-weeks safety follow-up)</time_frame>
        <population>All participants who received at least 1 dose of investigational product and had a baseline and at least 1 post-baseline result. Only participants who tested positive for anti-Efavaleukin alfa antibodies were analyzed for presence of anti-IL2 neutralizing antibodies. Only cohorts with enrolled participants are included.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 1b: Placebo</title>
            <description>Matching placebo administered via subcutaneous injection for a total of up to 12 weeks. Participants received placebo in 1 of 2 dosing schedules (i.e. dosing schedule A [less frequent] or schedule B [more frequent]).</description>
          </group>
          <group group_id="O2">
            <title>Phase 1b: Efavaleukin Alfa Cohort 1</title>
            <description>A low dose of Efavaleukin alfa administered via subcutaneous injection using dosing schedule A (less frequent than schedule B) for a total of up to 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Phase 1b: Efavaleukin Alfa Cohort 2</title>
            <description>A high dose of Efavaleukin alfa administered via subcutaneous injection using dosing schedule A (less frequent than schedule B) for a total of up to 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Phase 1b: Efavaleukin Alfa Cohort 3</title>
            <description>A medium dose of Efavaleukin alfa administered via subcutaneous injection using dosing schedule B (more frequent than schedule A) for a total of up to 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 1b: Number of Participants With Anti-Efavaleukin Alfa Neutralizing Antibodies and Anti-IL-2 Neutralizing Antibodies</title>
          <description>The number of participants who tested positive for anti-Efavaleukin alfa neutralizing antibodies and number of participants with anti-IL2 neutralizing antibodies who tested negative or no result at baseline are reported.</description>
          <population>All participants who received at least 1 dose of investigational product and had a baseline and at least 1 post-baseline result. Only participants who tested positive for anti-Efavaleukin alfa antibodies were analyzed for presence of anti-IL2 neutralizing antibodies. Only cohorts with enrolled participants are included.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Neutralizing anti-AMG 592 antibodies positive post-baseline with a negative or no result at baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutralizing anti-IL2 antibody positive post-baseline with a negative or no result at baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 2a: Number of Participants Who Achieved an American College of Rheumatology 50 Percent Improvement Criteria (ACR 50) or 70 Percent Improvement Criteria (ACR 70) at Week 12</title>
        <description>ACR 50 and ACR 70 response defined as at least 50 percent or 70 percent improvement from baseline in both tender and swollen joint counts, and a 50 percent or 70 percent improvement or more in at least 3 of the following 5 criteria:&#xD;
physician global assessment of disease activity (PGA)&#xD;
subject global assessment of disease activity (SGA)&#xD;
patient global assessment of joint pain&#xD;
subject self-assessment of disability (HAQ-DI)&#xD;
C-Reactive Protein (CRP)</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>No data is available for phase 2a. Study was terminated prior to any participants enrolling in phase 2a.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 2a: Placebo</title>
            <description>Matching placebo administered via subcutaneous injection, depending on the recommended phase 2 dose (RP2D) and dosing schedule as determined in phase 1b, for a total of up to 12 weeks.&#xD;
The study was terminated prior to the start of phase 2a and no participants were enrolled.</description>
          </group>
          <group group_id="O2">
            <title>Phase 2a: Efavaleukin Alfa</title>
            <description>Efavaleukin alfa administered via subcutaneous injection depending on the RP2D and dosing schedule determined in phase 1b, for up to a total of up to 12 weeks.&#xD;
The study was terminated prior to the start of phase 2a and no participants were enrolled.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 2a: Number of Participants Who Achieved an American College of Rheumatology 50 Percent Improvement Criteria (ACR 50) or 70 Percent Improvement Criteria (ACR 70) at Week 12</title>
          <description>ACR 50 and ACR 70 response defined as at least 50 percent or 70 percent improvement from baseline in both tender and swollen joint counts, and a 50 percent or 70 percent improvement or more in at least 3 of the following 5 criteria:&#xD;
physician global assessment of disease activity (PGA)&#xD;
subject global assessment of disease activity (SGA)&#xD;
patient global assessment of joint pain&#xD;
subject self-assessment of disability (HAQ-DI)&#xD;
C-Reactive Protein (CRP)</description>
          <population>No data is available for phase 2a. Study was terminated prior to any participants enrolling in phase 2a.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ACR 50</title>
            </class>
            <class>
              <title>ACR 70</title>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 2a: Change From Baseline in Disease Activity Score (28 Joint) Calculated Using The Erythrocyte Sedimentation Rate Formula (DAS28-ESR) at Week 12</title>
        <description>Change from baseline in DAS28-ER at Week 12. DAS28-ESR was to assess disease activity in patients with rheumatoid arthritis. DAS28-ESR is a composite score that includes 4 variables: tender joint count (TJC) (based on 28 joints); swollen joint count (SJC) (based on 28 joints); participant's global assessment of health activity using 100 mm VAS: range 0 (no pain) to 100 (maximum pain imaginable); marker of inflammation assessed by ESR in mm/h. DAS28-ESR total score range from 0-10, higher score indicates more disease activity.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>No data is available for phase 2a. Study was terminated prior to any participants enrolling in phase 2a.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 2a: Placebo</title>
            <description>Matching placebo administered via subcutaneous injection, depending on the recommended phase 2 dose (RP2D) and dosing schedule as determined in phase 1b, for a total of up to 12 weeks.&#xD;
The study was terminated prior to the start of phase 2a and no participants were enrolled.</description>
          </group>
          <group group_id="O2">
            <title>Phase 2a: Efavaleukin Alfa</title>
            <description>Efavaleukin alfa administered via subcutaneous injection depending on the RP2D and dosing schedule determined in phase 1b, for up to a total of up to 12 weeks.&#xD;
The study was terminated prior to the start of phase 2a and no participants were enrolled.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 2a: Change From Baseline in Disease Activity Score (28 Joint) Calculated Using The Erythrocyte Sedimentation Rate Formula (DAS28-ESR) at Week 12</title>
          <description>Change from baseline in DAS28-ER at Week 12. DAS28-ESR was to assess disease activity in patients with rheumatoid arthritis. DAS28-ESR is a composite score that includes 4 variables: tender joint count (TJC) (based on 28 joints); swollen joint count (SJC) (based on 28 joints); participant's global assessment of health activity using 100 mm VAS: range 0 (no pain) to 100 (maximum pain imaginable); marker of inflammation assessed by ESR in mm/h. DAS28-ESR total score range from 0-10, higher score indicates more disease activity.</description>
          <population>No data is available for phase 2a. Study was terminated prior to any participants enrolling in phase 2a.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 2a: Change From Baseline in Disease Activity Score (28 Joint) Calculated Using the C-reactive Protein Formula (DAS-28-CRP) at Week 12</title>
        <description>Change from baseline in DAS28-CRP at Week 12. 2. DAS28-CRP was to assess disease activity in patients with rheumatoid arthritis. DAS28-CRP is a composite score that includes 4 variables: TJC (based on 28 joints); SJC (based on 28 joints); participant's global assessment of health activity using 100 mm VAS: range 0 (no pain) to 100 (maximum pain imaginable); marker of inflammation assessed by CRP in mg/L. DAS28-CRP total score range from 0-10, higher score indicates more disease activity.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>No data is available for phase 2a. Study was terminated prior to any participants enrolling in phase 2a.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 2a: Placebo</title>
            <description>Matching placebo administered via subcutaneous injection, depending on the recommended phase 2 dose (RP2D) and dosing schedule as determined in phase 1b, for a total of up to 12 weeks.&#xD;
The study was terminated prior to the start of phase 2a and no participants were enrolled.</description>
          </group>
          <group group_id="O2">
            <title>Phase 2a: Efavaleukin Alfa</title>
            <description>Efavaleukin alfa administered via subcutaneous injection depending on the RP2D and dosing schedule determined in phase 1b, for up to a total of up to 12 weeks.&#xD;
The study was terminated prior to the start of phase 2a and no participants were enrolled.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 2a: Change From Baseline in Disease Activity Score (28 Joint) Calculated Using the C-reactive Protein Formula (DAS-28-CRP) at Week 12</title>
          <description>Change from baseline in DAS28-CRP at Week 12. 2. DAS28-CRP was to assess disease activity in patients with rheumatoid arthritis. DAS28-CRP is a composite score that includes 4 variables: TJC (based on 28 joints); SJC (based on 28 joints); participant's global assessment of health activity using 100 mm VAS: range 0 (no pain) to 100 (maximum pain imaginable); marker of inflammation assessed by CRP in mg/L. DAS28-CRP total score range from 0-10, higher score indicates more disease activity.</description>
          <population>No data is available for phase 2a. Study was terminated prior to any participants enrolling in phase 2a.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 2a: Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE)</title>
        <description>TEAEs were events with an onset after the administration of the first dose of study treatment.&#xD;
TEAEs were graded using the Common Terminology Criteria for Adverse Events (CTCAE).</description>
        <time_frame>Baseline up to end of study, maximum of 18 weeks (12-weeks double-blind treatment, 6-weeks safety follow-up)</time_frame>
        <population>No data is available for phase 2a. Study was terminated prior to any participants enrolling in phase 2a.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 2a: Placebo</title>
            <description>Matching placebo administered via subcutaneous injection, depending on the recommended phase 2 dose (RP2D) and dosing schedule as determined in phase 1b, for a total of up to 12 weeks.&#xD;
The study was terminated prior to the start of phase 2a and no participants were enrolled.</description>
          </group>
          <group group_id="O2">
            <title>Phase 2a: Efavaleukin Alfa</title>
            <description>Efavaleukin alfa administered via subcutaneous injection depending on the RP2D and dosing schedule determined in phase 1b, for up to a total of up to 12 weeks.&#xD;
The study was terminated prior to the start of phase 2a and no participants were enrolled.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 2a: Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE)</title>
          <description>TEAEs were events with an onset after the administration of the first dose of study treatment.&#xD;
TEAEs were graded using the Common Terminology Criteria for Adverse Events (CTCAE).</description>
          <population>No data is available for phase 2a. Study was terminated prior to any participants enrolling in phase 2a.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 2a: Number of Participants Who Experienced a Clinically Significant Change in Vital Signs</title>
        <description>Any changes in systolic/diastolic blood pressure, heart rate, respiratory rate, and temperature that were deemed as clinically significant by the Investigator were reported.</description>
        <time_frame>Baseline up to Week 12</time_frame>
        <population>No data is available for phase 2a. Study was terminated prior to any participants enrolling in phase 2a.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 2a: Placebo</title>
            <description>Matching placebo administered via subcutaneous injection, depending on the recommended phase 2 dose (RP2D) and dosing schedule as determined in phase 1b, for a total of up to 12 weeks.&#xD;
The study was terminated prior to the start of phase 2a and no participants were enrolled.</description>
          </group>
          <group group_id="O2">
            <title>Phase 2a: Efavaleukin Alfa</title>
            <description>Efavaleukin alfa administered via subcutaneous injection depending on the RP2D and dosing schedule determined in phase 1b, for up to a total of up to 12 weeks.&#xD;
The study was terminated prior to the start of phase 2a and no participants were enrolled.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 2a: Number of Participants Who Experienced a Clinically Significant Change in Vital Signs</title>
          <description>Any changes in systolic/diastolic blood pressure, heart rate, respiratory rate, and temperature that were deemed as clinically significant by the Investigator were reported.</description>
          <population>No data is available for phase 2a. Study was terminated prior to any participants enrolling in phase 2a.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 2a: Number of Participants Who Experienced a Clinically Significant Change in Laboratory Safety Tests</title>
        <description>Laboratory safety tests included chemistry and hematology parameters. Clinically significant laboratory safety tests were any events assessed as CTCAE Grade â‰¥3 at any post-baseline visit.&#xD;
Grade 3 Severe or medically significant but not immediately life-threatening; hospitalization or prolonged hospitalization indicated; disabling; limited self care ADL.&#xD;
Grade 4 Life-threatening consequences; urgent interventions indicated.</description>
        <time_frame>Day 1 up to end of study, maximum of 18 weeks (12-weeks double-blind treatment, 6-weeks safety follow-up)</time_frame>
        <population>No data is available for phase 2a. Study was terminated prior to any participants enrolling in phase 2a.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 2a: Placebo</title>
            <description>Matching placebo administered via subcutaneous injection, depending on the recommended phase 2 dose (RP2D) and dosing schedule as determined in phase 1b, for a total of up to 12 weeks.&#xD;
The study was terminated prior to the start of phase 2a and no participants were enrolled.</description>
          </group>
          <group group_id="O2">
            <title>Phase 2a: Efavaleukin Alfa</title>
            <description>Efavaleukin alfa administered via subcutaneous injection depending on the RP2D and dosing schedule determined in phase 1b, for up to a total of up to 12 weeks.&#xD;
The study was terminated prior to the start of phase 2a and no participants were enrolled.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 2a: Number of Participants Who Experienced a Clinically Significant Change in Laboratory Safety Tests</title>
          <description>Laboratory safety tests included chemistry and hematology parameters. Clinically significant laboratory safety tests were any events assessed as CTCAE Grade â‰¥3 at any post-baseline visit.&#xD;
Grade 3 Severe or medically significant but not immediately life-threatening; hospitalization or prolonged hospitalization indicated; disabling; limited self care ADL.&#xD;
Grade 4 Life-threatening consequences; urgent interventions indicated.</description>
          <population>No data is available for phase 2a. Study was terminated prior to any participants enrolling in phase 2a.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 2a: Efavaleukin Alfa Serum Concentration</title>
        <description>A summary of mean serum concentrations of Efavaleukin alfa over time.</description>
        <time_frame>Day 1 (pre-dose) and weeks 2, 4, 6, 8, 10 and 12</time_frame>
        <population>No data is available for phase 2a. Study was terminated prior to any participants enrolling in phase 2a.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 2a: Placebo</title>
            <description>Matching placebo administered via subcutaneous injection, depending on the recommended phase 2 dose (RP2D) and dosing schedule as determined in phase 1b, for a total of up to 12 weeks.&#xD;
The study was terminated prior to the start of phase 2a and no participants were enrolled.</description>
          </group>
          <group group_id="O2">
            <title>Phase 2a: Efavaleukin Alfa</title>
            <description>Efavaleukin alfa administered via subcutaneous injection depending on the RP2D and dosing schedule determined in phase 1b, for up to a total of up to 12 weeks.&#xD;
The study was terminated prior to the start of phase 2a and no participants were enrolled.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 2a: Efavaleukin Alfa Serum Concentration</title>
          <description>A summary of mean serum concentrations of Efavaleukin alfa over time.</description>
          <population>No data is available for phase 2a. Study was terminated prior to any participants enrolling in phase 2a.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 2a: Maximum Observed Serum Concentration (Cmax) of Efavaleukin Alfa</title>
        <time_frame>Day 1 (pre-dose) and weeks 2, 4, 6, 8, 10 and 12</time_frame>
        <population>No data is available for phase 2a. Study was terminated prior to any participants enrolling in phase 2a.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 2a: Placebo</title>
            <description>Matching placebo administered via subcutaneous injection, depending on the recommended phase 2 dose (RP2D) and dosing schedule as determined in phase 1b, for a total of up to 12 weeks.&#xD;
The study was terminated prior to the start of phase 2a and no participants were enrolled.</description>
          </group>
          <group group_id="O2">
            <title>Phase 2a: Efavaleukin Alfa</title>
            <description>Efavaleukin alfa administered via subcutaneous injection depending on the RP2D and dosing schedule determined in phase 1b, for up to a total of up to 12 weeks.&#xD;
The study was terminated prior to the start of phase 2a and no participants were enrolled.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 2a: Maximum Observed Serum Concentration (Cmax) of Efavaleukin Alfa</title>
          <population>No data is available for phase 2a. Study was terminated prior to any participants enrolling in phase 2a.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 2a: Time to Maximum Observed Serum Concentration (Tmax) of Efavaleukin Alfa</title>
        <time_frame>Day 1 (pre-dose) and weeks 2, 4, 6, 8, 10 and 12</time_frame>
        <population>No data is available for phase 2a. Study was terminated prior to any participants enrolling in phase 2a.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 2a: Placebo</title>
            <description>Matching placebo administered via subcutaneous injection, depending on the recommended phase 2 dose (RP2D) and dosing schedule as determined in phase 1b, for a total of up to 12 weeks.&#xD;
The study was terminated prior to the start of phase 2a and no participants were enrolled.</description>
          </group>
          <group group_id="O2">
            <title>Phase 2a: Efavaleukin Alfa</title>
            <description>Efavaleukin alfa administered via subcutaneous injection depending on the RP2D and dosing schedule determined in phase 1b, for up to a total of up to 12 weeks.&#xD;
The study was terminated prior to the start of phase 2a and no participants were enrolled.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 2a: Time to Maximum Observed Serum Concentration (Tmax) of Efavaleukin Alfa</title>
          <population>No data is available for phase 2a. Study was terminated prior to any participants enrolling in phase 2a.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 2a: Area Under the Concentration-time Curve (AUC) of Efavaleukin Alfa</title>
        <time_frame>Day 1 (pre-dose) and weeks 2, 4, 6, 8, 10 and 12</time_frame>
        <population>No data is available for phase 2a. Study was terminated prior to any participants enrolling in phase 2a.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 2a: Placebo</title>
            <description>Matching placebo administered via subcutaneous injection, depending on the recommended phase 2 dose (RP2D) and dosing schedule as determined in phase 1b, for a total of up to 12 weeks.&#xD;
The study was terminated prior to the start of phase 2a and no participants were enrolled.</description>
          </group>
          <group group_id="O2">
            <title>Phase 2a: Efavaleukin Alfa</title>
            <description>Efavaleukin alfa administered via subcutaneous injection depending on the RP2D and dosing schedule determined in phase 1b, for up to a total of up to 12 weeks.&#xD;
The study was terminated prior to the start of phase 2a and no participants were enrolled.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 2a: Area Under the Concentration-time Curve (AUC) of Efavaleukin Alfa</title>
          <population>No data is available for phase 2a. Study was terminated prior to any participants enrolling in phase 2a.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Day 1 up to end of study, maximum of 18 weeks (12-weeks double-blind treatment, 6-weeks safety follow-up)</time_frame>
      <desc>All-cause mortality is reported for all participants enrolled/randomized in the study. Treatment emergent serious adverse events and other adverse events, including disease-related events are reported for all participants who received at least one dose of study drug.&#xD;
No data is available for phase 1b Cohort 4 or phase 2a cohorts as the study was terminated prior to any participants enrolling.</desc>
      <group_list>
        <group group_id="E1">
          <title>Phase 1b: Placebo</title>
          <description>Matching placebo administered via subcutaneous injection for a total of up to 12 weeks. Participants received placebo in 1 of 2 dosing schedules (i.e. dosing schedule A [less frequent] or schedule B [more frequent]).</description>
        </group>
        <group group_id="E2">
          <title>Phase 1b: Efavaleukin Alfa Cohort 1</title>
          <description>A low dose of Efavaleukin alfa administered via subcutaneous injection using dosing schedule A (less frequent than schedule B) for a total of up to 12 weeks.</description>
        </group>
        <group group_id="E3">
          <title>Phase 1b: Efavaleukin Alfa Cohort 2</title>
          <description>A high dose of Efavaleukin alfa administered via subcutaneous injection using dosing schedule A (less frequent than schedule B) for a total of up to 12 weeks.</description>
        </group>
        <group group_id="E4">
          <title>Phase 1b: Efavaleukin Alfa Cohort 3</title>
          <description>A medium dose of Efavaleukin alfa administered via subcutaneous injection using dosing schedule B (more frequent than schedule A) for a total of up to 12 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 22.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 22.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Eosinophilia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Conjunctival haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Swelling of eyelid</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Large intestine polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Lower gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Swollen tongue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Administration site reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Injection site hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Injection site pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Peripheral swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gingivitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Administration related reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Arthropod bite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Body temperature increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Eosinophil count increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Joint stiffness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Joint swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Musculoskeletal stiffness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Rheumatoid arthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Dizziness postural</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Dysmenorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Blister</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Drug eruption</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Skin burning sensation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Skin lesion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Skin swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Enrollment of the phase 1b part of this study was stopped as of 30 September 2019 due to data that suggested that there is not sufficient benefit-risk for the use of Efavaleukin alfa plus standard of care therapy in this study population. The study was terminated prior to the enrollment of any participants into phase 1b Cohort 4 and phase 2a cohorts.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Amgen Inc.</organization>
      <phone>866-572-6436</phone>
      <email>medinfo@amgen.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

